JP7634993B2 - 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用 - Google Patents

抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用 Download PDF

Info

Publication number
JP7634993B2
JP7634993B2 JP2020570743A JP2020570743A JP7634993B2 JP 7634993 B2 JP7634993 B2 JP 7634993B2 JP 2020570743 A JP2020570743 A JP 2020570743A JP 2020570743 A JP2020570743 A JP 2020570743A JP 7634993 B2 JP7634993 B2 JP 7634993B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
amino acid
seq
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020570743A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019246176A5 (https=
JP2021527424A5 (https=
JP2021527424A (ja
Inventor
ダン チャロソーン，
ローリ シー． モートン，
リンドン ミトナウル，
ケーディー ライ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2021527424A publication Critical patent/JP2021527424A/ja
Publication of JPWO2019246176A5 publication Critical patent/JPWO2019246176A5/ja
Publication of JP2021527424A5 publication Critical patent/JP2021527424A5/ja
Priority to JP2024099610A priority Critical patent/JP2024116399A/ja
Application granted granted Critical
Publication of JP7634993B2 publication Critical patent/JP7634993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F3/00—Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements
    • H03F3/45—Differential amplifiers
    • H03F3/45071—Differential amplifiers with semiconductor devices only
    • H03F3/45076—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier
    • H03F3/45475—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier using IC blocks as the active amplifying circuit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2203/00—Indexing scheme relating to amplifiers with only discharge tubes or only semiconductor devices as amplifying elements covered by H03F3/00
    • H03F2203/45—Indexing scheme relating to differential amplifiers
    • H03F2203/45444—Indexing scheme relating to differential amplifiers the CMCL comprising a sample and hold circuit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Power Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Amplifiers (AREA)
JP2020570743A 2018-06-19 2019-06-19 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用 Active JP7634993B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024099610A JP2024116399A (ja) 2018-06-19 2024-06-20 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687144P 2018-06-19 2018-06-19
US62/687,144 2018-06-19
PCT/US2019/037865 WO2019246176A1 (en) 2018-06-19 2019-06-19 Anti-factor xii/xiia antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024099610A Division JP2024116399A (ja) 2018-06-19 2024-06-20 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用

Publications (4)

Publication Number Publication Date
JP2021527424A JP2021527424A (ja) 2021-10-14
JPWO2019246176A5 JPWO2019246176A5 (https=) 2022-06-20
JP2021527424A5 JP2021527424A5 (https=) 2022-06-20
JP7634993B2 true JP7634993B2 (ja) 2025-02-25

Family

ID=67263076

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570743A Active JP7634993B2 (ja) 2018-06-19 2019-06-19 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
JP2024099610A Pending JP2024116399A (ja) 2018-06-19 2024-06-20 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024099610A Pending JP2024116399A (ja) 2018-06-19 2024-06-20 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用

Country Status (12)

Country Link
US (1) US12068729B2 (https=)
EP (1) EP3810270A1 (https=)
JP (2) JP7634993B2 (https=)
KR (1) KR20210022650A (https=)
CN (1) CN112437682B (https=)
AU (1) AU2019288299B2 (https=)
CA (1) CA3104470A1 (https=)
EA (1) EA202190056A1 (https=)
IL (1) IL279529A (https=)
MA (1) MA52966A (https=)
MX (1) MX2020013894A (https=)
WO (1) WO2019246176A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240352150A2 (en) * 2020-06-16 2024-10-24 Ningbo Comgen Biotech Co., Ltd. Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof
JP2023531315A (ja) * 2020-07-03 2023-07-21 シーエスエル・イノベーション・プロプライエタリー・リミテッド 第ｘｉｉ因子抗原結合タンパク質の高濃度製剤
EP4729546A1 (en) * 2023-06-16 2026-04-22 Jiangsu BioJeTay Biotechnology Co., Ltd. Antibody specifically recognizing factor xiia and use thereof
IL325613A (en) * 2023-07-19 2026-02-01 Regeneron Pharma Antibodies against factor xii/xiia and their uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089493A1 (en) 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
JP2014523253A (ja) 2011-07-22 2014-09-11 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
CA2082643A1 (en) 1990-05-10 1991-11-11 Jan H. Nuijens Inhibitors of factor xii activation and applications thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6891394B1 (en) * 2002-06-04 2005-05-10 Actel Corporation Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers
US7378867B1 (en) * 2002-06-04 2008-05-27 Actel Corporation Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CA2591786C (en) 2004-12-23 2013-07-16 Bernhard Nieswandt Prevention of thrombus formation and/or stabilization
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US7541838B2 (en) * 2007-03-27 2009-06-02 Intel Corporation Transmitter swing control circuit and method
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
EP2384766A1 (en) * 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel antibody to a carbonic anhydrase
CN103415301A (zh) 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
BR112014001255B1 (pt) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR101461652B1 (ko) * 2011-12-16 2014-11-21 주식회사 삼양바이오팜 유착방지용 조성물, 이를 포함하는 유착방지기능을 갖는 수술용 메쉬 복합체 및 이의 제조 방법
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
TWI613215B (zh) * 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
KR20150139089A (ko) * 2014-06-02 2015-12-11 한국전자통신연구원 멀티플라이어 및 다중 입력 증폭기를 포함하는 전류-전압 변환 증폭 회로
US10259874B2 (en) * 2014-10-27 2019-04-16 Agency For Science, Technology And Research Anti-TIM-3 antibodies
CN111919424A (zh) * 2018-07-02 2020-11-10 拉姆伯斯公司 利用早期高阶符号检测用于判决反馈均衡的方法和电路

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523253A (ja) 2011-07-22 2014-09-11 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用
WO2014089493A1 (en) 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD，2014年，Vol.123, No.11，pp.1739-1746

Also Published As

Publication number Publication date
CA3104470A1 (en) 2019-12-26
US12068729B2 (en) 2024-08-20
JP2024116399A (ja) 2024-08-27
JP2021527424A (ja) 2021-10-14
EP3810270A1 (en) 2021-04-28
KR20210022650A (ko) 2021-03-03
MX2020013894A (es) 2021-05-27
AU2019288299B2 (en) 2026-02-05
CN112437682A (zh) 2021-03-02
EA202190056A1 (ru) 2021-05-28
WO2019246176A8 (en) 2020-10-08
WO2019246176A1 (en) 2019-12-26
MA52966A (fr) 2021-04-28
IL279529A (en) 2021-01-31
US20210203292A1 (en) 2021-07-01
CN112437682B (zh) 2024-11-05
AU2019288299A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
JP7682964B2 (ja) 抗ｃ５抗体及びそれらの使用
JP2024116399A (ja) 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
US20250333524A1 (en) Immunoglobulin proteins that bind to npr1 agonists
US12304969B2 (en) Factor XI A2 domain-binding antibodies and methods of use thereof
US20240190996A1 (en) Factor xi catalytic domain-binding antibodies and methods of use thereof
WO2025019789A1 (en) ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF
EA048528B1 (ru) АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
JP7807238B2 (ja) 骨形成タンパク質６に対するヒト抗体
EA052707B1 (ru) Антитела, связывающие домен a2 фактора xi, и способы их использования
US9751936B2 (en) Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
EA041355B1 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА К ТОКСИНУ ГЕМОЛИЗИНУ А S.aureus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250212

R150 Certificate of patent or registration of utility model

Ref document number: 7634993

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150